Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Cephalexin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 21 USDMF, 4 JDMF, 5 NDC API, 3 Listed Suppliers, $ API Reference Price

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

163 FDF Dossiers, 97 FDA Orange Book, 6 Europe, 6 Canada, 2 South Africa, 52 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 750MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 Rochem International Inc, 6 SPI Pharma, 14 DKSH, 1 Pharm-RX Chemical, 6 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 1 Clariant, 7 DFE Pharma, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 26 Kerry, 1 Kima Chemical, 3 Lonza Capsugel, 13 Microlex e.U, 1 Nanjing Bold Chemical, 2 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 23 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 1 The Dow Chemical Company, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders, 34 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 24 Direct Compression, 19 Granulation, 18 Solubilizers, 17 Coating Systems & Additives, 15 Lubricants & Glidants, 14 Taste Masking, 13 Topical, 12 Co-Processed Excipients, 11 Rheology Modifiers, 10 Film Formers & Plasticizers, 10 Parenteral, 8 Empty Capsules, 7 Emulsifying Agents, 7 Controlled & Modified Release, 6 Chewable & Orodispersible Aids, 4 Surfactant & Foaming Agents, 3 API Stability Enhancers, 3 Coloring Agents

DIGITAL CONTENT

25 News #PharmaBuzz

25 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 12 Regulatory FDF Prices

MARKET PLACE

14 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Exclusivities

2 US Exclusivities

REF. STANDARDS & IMPURITIES

2 USP, 10 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
28/03/2025	ACS DOBFAR SPA	Italy	ACS DOBFAR S. p. A.	218MF10523	Cephalexin	2006-05-18	2018-04-17	Viale Addetta, 4/12, 20067 Tribiano (Milan) Italy
28/03/2025	ADL BioPharma	Spain	Antibiotics S. A. Leon Factory	220MF10148	Cephalexin	2008-06-10	2008-06-10	Avenida de Antibioticos 59/61 24009 Leon, Spain

Cephalexin

Cephalexin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers

21 USDMF

4 JDMF

5 NDC API

3 Listed Suppliers

$ API Reference Price

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

163 FDF Dossiers

97 FDA Orange Book

6 Europe

6 Canada

2 South Africa

52 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 750MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

4 Rochem International Inc

6 SPI Pharma

14 DKSH

1 Pharm-RX Chemical

6 Faran Shimi Pharmaceutical

5 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

1 Pfanstiehl

4 ACG Worldwide

6 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

9 BASF

1 Clariant

7 DFE Pharma

2 Finar

9 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

26 Kerry

1 Kima Chemical

3 Lonza Capsugel

13 Microlex e.U

1 Nanjing Bold Chemical

2 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qualicaps

23 Roquette

8 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

12 Sigachi Industries

1 The Dow Chemical Company

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

64 Fillers, Diluents & Binders

34 Thickeners and Stabilizers

26 Disintegrants & Superdisintegrants

24 Direct Compression

19 Granulation

18 Solubilizers

17 Coating Systems & Additives

15 Lubricants & Glidants

14 Taste Masking

13 Topical

12 Co-Processed Excipients

11 Rheology Modifiers

10 Film Formers & Plasticizers

10 Parenteral

8 Empty Capsules

7 Emulsifying Agents

CAPSULE;ORAL - EQ 250MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 333MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 500MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 750MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons